Caredx Inc Stock
€31.80
Your prediction
Description CareDx
CareDx is a publicly-traded biotechnology company that specializes in developing and commercializing diagnostic solutions for solid organ and cell-based transplantation. The company's main focus is on transplant patients and developing solutions that offer improved outcomes and streamlined processes for medical professionals.
CareDx provides a range of products and services, including diagnostic assays, monitoring services, and cloud-based software solutions. These products and services are designed to help healthcare providers more accurately monitor transplant patients, predict potential clinical issues, and manage post-transplant care more effectively.
The company was founded in 1998 and is headquartered in Brisbane, California. CareDx's stock is listed on the Nasdaq Global Market under the ticker symbol "CDNA". The company has a market capitalization of around $2.6 billion as of June 2021, and its stock has shown strong growth in recent years, driven by rising demand for its products and services.
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Financial data and news for CareDx
sharewise wants to provide you with the best news and tools for CareDx, so we directly link to the best financial data sources.
Financials
News
CareDx Sharpens Precision Diagnostics Push With Naveris Deal, AlloHeme Plans
Key Points
- Interested in CareDx, Inc.? Here are five stocks we like better.
- CareDx is pivoting deeper into precision diagnostics by divesting its lab products unit and using the proceeds to
CareDx Highlights 39% Q1 Growth, Naveris Oncology Push at Jefferies
Key Points
- Interested in CareDx, Inc.? Here are five stocks we like better.
- CareDx posted strong Q1 results, with revenue up 39% year over year and Testing Services volume up 17%. The company
CareDx's CEO Sells 17K Shares
CareDx (NASDAQ:CDNA), a leader in transplant diagnostics, saw a key insider reduce his direct holdings amid a series of scheduled transactions.
John Hanna, President and CEO of CareDx, disclosed the
CareDx (CDNA) Q1 2026 Earnings Call Transcript
Image source: The Motley Fool.
Tuesday, April 28, 2026 at 4:30 p.m. ET
CareDx (NASDAQ:CDNA) announced the divestiture of its Lab Products business for $170 million upfront, expected to close by the
CareDx's CEO Conducts Multiple Sale of Shares Towards the End of January 2026
John Walter Hanna Jr., President and CEO of CareDx (NASDAQ:CDNA), directly sold 19,480 shares in multiple open-market transactions on Jan. 21 and Jan. 22, 2026, for a total value of approximately
CareDx President and CEO Sells 19,000 Shares for $412,000
John Hanna, President and CEO of CareDx (NASDAQ:CDNA), directly sold 19,480 shares in multiple open-market transactions on Jan. 21, 2026 and Jan. 22, 2026, with an aggregate transaction value of